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ABSTRACT 
Acute heart failure (AHF) patients rarely present complaining of ‘acute heart failure.’ Rather, 
they initially present to the emergency department (ED) with a myriad of chief complaints, 
symptoms, and physical exam findings. Such heterogeneity prompts an initially broad 
differential diagnosis; securing the correct diagnosis can be challenging.  Although AHF may be 
the ultimate diagnosis, the precipitant of decompensation must also be sought and addressed.  
For those AHF patients who present in respiratory or circulatory failure requiring immediate 
stabilization, treatment begins even while the diagnosis is uncertain. 
The initial diagnostic workup consists of a thorough history and exam (with a particular focus on 
the cause of decompensation), an EKG, chest X-ray, laboratory testing, and point-of-care 
ultrasonography performed by a qualified clinician or technologist. We recommend initial 
treatment be guided by presenting phenotype. Hypertensive patients, particularly those in 
severe distress and markedly elevated blood pressure, should be treated aggressively with 
vasodilators, most commonly nitroglycerin. Normotensive patients generally require significant 
diuresis with intravenous loop diuretics. A small minority of patients present with hypotension 
or circulatory collapse. These patients are the most difficult to manage and require careful 
assessment of intra- and extra-vascular volume status. After stabilization, diagnosis, and 
management, most ED patients with AHF in the United States (US) are admitted. While this is 
understandable, it may be unnecessary. Ongoing research to improve diagnosis, initial 
treatment, risk stratification, and disposition may help ease the tremendous public health 
burden of AHF.   
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Abbreviations: 
 
ACC/AHA – American College of Cardiology / American Heart Association 
 
ACEI – ace inhibitor 
 
ACS – acute coronary syndrome 
 
AHF – acute heart failure 
 
ASCEND-HF - Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart 
Failure 
 
BNP – brain natriuretic peptide 
 
BP – blood pressure 
 
ED – emergency department 
 
EF – ejection fraction 
 
EKG – electrocardiogram 
 
ESC – European Society of Cardiology 
 
HF – heart failure 
 
ICU – intensive care unit 
 
IV – intravenous 
 
IVC – inferior vena cava 
 
IVC-CI – inferior vena cava collapsibility index 
 
LOS – length of stay 
 
NIPPV – non-invasive positive pressure ventilation 
 
NTG – nitroglycerin 
 
SBP – systolic blood pressure 
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STEMI – ST-elevation myocardial infarction 
 
US – United States  
 
 
Keywords:  
Heart failure; acute heart failure; decompensated heart failure; emergency department 
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Diagnosis and management begins in the emergency department (ED) for the vast 
majority of patients hospitalized with acute heart failure (AHF).  Unfortunately, the evidence 
base for ED management is limited.1,2  This lack of evidence, combined with the heterogeneity 
of the AHF patient population, results in tremendous variability in clinical practice. The 
potential impact of ED management is significant, as diagnostic delay or sub-optimal treatment 
may have significant downstream consequences. Perhaps the costliest ED management 
decision is deciding who does or does not require hospitalization, the most expensive resource 
in healthcare.3,4  As epidemiology and pathophysiology of AHF are covered elsewhere, this 
review focuses on initial ED management.  
 
Stabilization 
Occasionally, patients with possible AHF present in extremis or near respiratory failure.  In 
these instances, the diagnostic work up and management occur in parallel.   Importantly, the 
precipitating cause of the patient’s dramatic presentation must be simultaneously identified 
and treated.  Arrhythmias, infection, and acute coronary syndromes are just a few potential 
precipitants.  The classical teaching of ensuring “Airway, Breathing, and Circulation” first is 
worth reiterating.   
Obtunded patients with severe respiratory failure will likely require endotracheal 
intubation and mechanical ventilation.5 For patients with respiratory distress who are awake 
and cooperative, early initiation of non-invasive positive pressure ventilation (NIPPV) 
significantly decreases mortality and need for intubation.6 NIPPV can be instituted even if the 
diagnosis of AHF is in doubt, as evidence suggests benefit even in undifferentiated severe 
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dyspnea.7 The increased intra-thoracic pressure from NIPPV may decrease blood pressure (BP), 
but this is uncommon clinically and more likely with endotracheal intubation. Once the patient 
has been stabilized, the focus turns to diagnosis. 
 
 
Initial Diagnosis and Assessment 
Fortunately, most AHF patients do not present in extremis. Establishing the diagnosis is 
the sine qua non of medicine, but is not always easy.  It is worth noting the myriad of different 
patient complaints: Fatigue, dizziness, shortness of breath, chest pain, weakness, exercise 
intolerance, swelling, and weight gain are all symptoms prompting consideration of AHF as the 
cause.   
The clinical presentation of AHF varies widely, ranging from mildly worsening heart 
failure, de novo or new onset HF, to overt cardiogenic shock, to hypertensive flash pulmonary 
edema.  Despite the high prevalence of AHF in the ED setting, misdiagnosis occurs in 14-29% of 
patients8-11.  Heterogeneous pathophysiology and phenotypic expression, varied underlying 
causes and precipitants, and substantial co-morbid burden underlie the challenges of 
diagnosing this syndrome. Nevertheless, timely and accurate diagnosis of AHF is critical to 
preventing delays in treatment, which have been associated with increased risk of inpatient 
mortality and longer length of stay (LOS).12-14.   
Unfortunately, no single historical variable, symptom, physical exam finding, biomarker, 
or imaging modality is sensitive enough to sufficiently exclude the diagnosis of AHF. Dyspnea is 
the most common symptom prompting patients with AHF to seek care15, and is most often due 
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to vascular congestion. Discriminating AHF from other causes of dyspnea, however, remains 
challenging, especially for those patients without a preexisting diagnosis of heart failure (HF) 
and those with comorbidities, such as chronic obstructive pulmonary disease. Symptoms 
classically associated with HF, such as orthopnea and paroxysmal nocturnal dyspnea are 
reported by only half of patients with AHF and are less than 75% specific for the diagnosis16. 
The physical exam finding with the highest likelihood ratio (LR+) is an S3 gallop (LR+ 4.0 [95%CI 
2.7-5.9]), but the absence of this finding has minimal effect on changing the pre-test probability 
of AHF (LR-  0.91 [95%CI 0.89-0.95])16. Jugular venous distension and the hepatojugular reflex 
are more specific, but are insensitive and dependent on the examiner.   Despite knowledge that 
congestion is the primary underlying cause of patient signs and symptoms, measuring 
congestion with a high degree of intra and interobserver reliability remains challenging.17,18 
Natriuretic peptides are the most useful biomarkers for excluding the diagnosis of 
AHF19.  Cutoff points of 100 pg/mL and 300 pg/mL for brain natriuretic peptide (BNP) and  N-
terminal (NT)-proBNP, respectively, substantially reduce the post-test probability of AHF (LR-  
0.1) in patients presenting to the ED with dyspnea16. Very high BNP values are modestly helpful 
in ruling in AHF, but intermediate values (100-800 pg/mL for BNP) lack diagnostic specificity.  
Likelihood ratios associated with even the most elevated NT-proBNP values only modestly favor 
the diagnosis of AHF16.  The specificity of these biomarkers above proposed cutoff points are 
limited by renal dysfunction and advanced age19. Other conditions to consider in patients with 
modestly elevated BNP values are acute respiratory distress syndrome20, pulmonary 
embolism21,22, pulmonary hypertension23, and valvular heart disease24.  While natriuretic 
peptides provide additive diagnostic value beyond clinical and historical variables25-27, several 
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studies have failed to demonstrate differences in patient-centered clinical outcomes beyond 
hospital LOS28,29 with the addition of diagnostic BNP testing. 
In addition to a basic metabolic profile and complete blood count, troponin testing 
should be considered in AHF patients. Occasionally, troponin testing may uncover occult acute 
coronary syndrome (ACS), an important precipitant of AHF.30,31 Importantly, an elevated 
troponin does not rule in ACS, as many AHF patients may have troponin release.32  With the 
recent approval in the US of higher sensitivity assays, a greater proportion of AHF patients will 
likely be identified with “abnormal” troponin values.33  Troponins also add prognostic 
information,30 but should not be considered a diagnostic test to rule in or out AHF.  However, 
higher sensitivity assays may demonstrate troponin release as an integral part of the AHF 
syndrome; one recent study demonstrated 98% of AHF patients have measurable troponin, 
with 81% above the 99th percentile. 34 Both BNP and troponin are recommended in guidelines 
for the assessment and risk-stratification of the AHF patient.35,36 
Given the limitations of laboratory testing in isolation, imaging plays a significant role in 
the diagnostic approach to AHF.  The chest radiograph is considered a key component of the 
diagnostic workup. Chest radiography can identify vascular engorgement, hilar redistribution, 
interstitial edema, and alveolar edema as well as alternative causes of dyspnea37.  While highly 
specific for AHF, these radiographic findings are poorly sensitive.25,38,39 One series found that 
cardiomegaly alone had moderate sensitivity (79%) and specificity (80%).25   
Lung ultrasound has emerged as a useful point-of-care tool for identifying pulmonary 
edema and diagnosing AHF.40,41  Sonographic detection of pulmonary edema is based on the 
identification of vertical artifacts called B-lines, which are thought to result from the 
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reverberation of sound waves off of fluid-filled pulmonary interstitium. When distributed 
diffusely in the proper clinical setting, B-lines represent cardiogenic pulmonary edema.  A 
positive lung ultrasound study, defined as two or more bilateral thoracic zones with ≥ 3 B-lines, 
has good discriminatory value with a LR+ of 7.4 (95% CI 4.2 -12.8).  A negative lung ultrasound 
study substantially lowers the probability of AHF (LR- 0.16 [95% CI 0.05-0.51])16.  The extent of 
pulmonary edema can also be semi-quantitatively measured by the sum of the number of B-
lines with high inter-rater reliability42-44.  B-line severity has been shown to correlate with other 
measures of pulmonary congestion45 and with the severity of AHF46,47. The ESC HF guidelines 
now includes lung ultrasound as a recommended diagnostic test to confirm pulmonary 
congestion37. 
Point-of-care ultrasound -determined estimates of intravascular volume and right atrial 
pressures can be made by measuring the diameter of the inferior vena cava (IVC) and 
percentage change in IVC diameter during the respiratory cycle. An IVC diameter that fails to 
substantially decrease with inspiration is considered to have a low collapsibility (or caval) index 
(IVC-CI), reflecting volume overload and high RAP.  The diagnostic performance of different 
cutoff values for IVC collapsibility index, ranging from 20%-50% have been tested in dyspneic 
patients presenting to the ED48-51.  Sensitivities of 80% or greater were achieved in studies that 
used an IVC-CI cutoff of 33% or greater49-51.  Specificities associated with these cut-offs ranged 
from 81%-87%. Alternative causes of a plethoric IVC include tricuspid regurgitation, pulmonary 
embolism, pulmonary hypertension, and right ventricular infarction. 
Echocardiography is integral to the diagnostic workup of HF.  While formal 
echocardiography is rarely available rapidly in the ED, focused cardiac ultrasound in the hands 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11 
of trained emergency physicians can be used as a point-of-care tool to assess global systolic 
dysfunction. Qualitative visual estimations of reduced versus normal ejection fraction (EF) can 
be made by assessing the inward movement of the interventricular septum and inferior wall of 
the left ventricle during systole and by observing the degree of excursion of the anterior leaflet 
of the mitral valve toward the interventricular septum during diastole.  These qualitative 
assessments correlate with more formal, quantitative echocardiographic measures of EF.52,53 
Reduced EF identified by emergency physicians using focused cardiac ultrasound discriminates 
AHF from other causes of dyspnea with sensitivities ranging from 77-83% and specificities 
ranging from 74-90% 48,54,55. However, sonographic assessments of dyspneic patients limited to 
this single variable would fail to identify HF patients with preserved EF. Identification of a 
restrictive pattern of diastolic filling using pulsed Doppler analysis of mitral inflow as a 
surrogate measure of elevated filling pressures assists in the diagnosis of AHF (LR+ 8.3 [95%CI 
4.0-16.9])54.  Acquisition and interpretation of mitral inflow and tissue Doppler data is currently 
beyond the scope of ED physicians who lack formal fellowship training. Diagnostic approaches 
that integrate lung, cardiac, and IVC assessments increase the specificity of diagnosing AHF in 
the ED beyond clinical gestalt, biomarkers, and lung ultrasound alone48,50,55.  Further research is 
needed to help delineate the role of focused cardiac ultrasound in the workup of AHF and how 
different sonographic assessments can be incorporated into diagnostic algorithms.  
Importantly, point of care US does not replace formal echocardiography.56 
  
Initial Management 
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Once the diagnosis is made, presenting phenotype and cause of exacerbation guides 
initial treatment. As mentioned earlier, first assuring respiratory and hemodynamic stability is 
paramount.  (See Table 1 for Goals of ED Management) While addressing the patient’s 
respiratory status, the precipitant of AHF should be sought and treated. For example, rapid 
atrial fibrillation (AF), ACS, pulmonary embolism, underlying infection or dietary indiscretion 
can all trigger AHF57. Often the precipitant is unclear or challenging to identify.  Complicating 
matters, co-morbid conditions may cloud the picture or add challenges to management.  A 
classic example is the patient with both chronic obstructive pulmonary disease and AHF; 
wheezing may be bronchial or ‘cardiac wheezing’, and one exacerbation may incite the other.  
While simultaneous treatment frequently occurs clinically, untoward effects (such as inciting AF 
with beta agonists) may be detrimental. 
 
 
Table 1 
Goals of ED Management (although written sequentially, steps may occur simultaneously)  
1. Ensure stability of Airway, Breathing, and Circulation or resuscitate immediately 
2. Identify and treat any other potential life threats (i.e. STEMI, dysrhythmias) 
3. Ensure diagnosis of AHF and begin treatment. 
4. Identify the precipitant of AHF and modify treatment if necessary. 
5. Consider the potential contribution of other co-morbid conditions and whether they 
require urgent treatment 
6. Re-evaluate patient to ensure improvement in symptoms, hemodynamics, and clinical 
impression 
7. Risk-stratify patient 
8. Disposition planning (admission, observation, discharge) 
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Initial Classification 
 As an initial guide, we recommend grouping patients with suspected AHF by systolic BP 
(SBP).58,59  As evidenced by registries, SBP is often high (>140mmHg) at the time of 
presentation.60  We recommend using cutpoints of > 140mmHg, 100-140 mmHg, and < 100 
mmHg to guide initial selection of pharmacologic therapy.58,59  While there is considerable 
overlap, simple categorization aids the busy clinician. As such, it is reasonable to assume the 
predominant pathophysiologic derangement in a patient based on presenting SBP. Notably, not 
all patients present with total volume overload; the prototypical example is the flash pulmonary 
edema patient.61-63  Such patients have also been described as ‘vascular failure’ or ‘volume 
redistribution’ patients.64-66 These patients most commonly present with elevated SBP.  Of 
note, the latest ESC HF guidelines also support dividing patients based on ‘cardiac’ (fluid 
overload predominates) vs. ‘vascular’ (hypertension predominates) phenotypes.1   
 
Initial Therapy 
 At the present time, no AHF therapy receives a Level I, Class A recommendation from 
guidelines,1,2 highlighting the lack of robust evidence from randomized studies. Therapies used 
today are largely the same as those employed 4 decades ago (Table 2).  Rotating tourniquets 
and phlebotomy are no longer used; whether this represents a major advance is debatable.   
Importantly, lack of high quality evidence from robust, randomized controlled trials does not 
equate with ineffectiveness in achieving symptom relief, hemodynamic improvement, and 
decongestion; all important targets of therapies. 
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Table 2: Therapeutic Options for the Early Treatment of AHF – A Historical Perspective 
197467 2017 
Sit the patient upright Sit the patient upright 
Oxygen Oxygen 
Positive pressure ventilation Positive pressure ventilation 
Morphine Morphine 
Diuretics Diuretics 
Intra-aortic balloon pump Intra-aortic balloon pump 
Phlebotomy Inotropes 
Rotating tourniquets Vasodilators / Nesiritide 
 
The Hypotensive AHF Patient  
Shock due solely to worsening HF rarely occurs relative to other types of AHF.68 
Given its relatively uncommon presentation combined with the complexity of these 
patients’ underlying pathophysiology, precipitant, cardiac structure, function, and resultant 
hemodynamic status, management can be challenging.  Patients with advanced HF may 
present with alarmingly low SBP.  This may, in fact, reflect their baseline SBP. Even when 
resuscitating shock, a common mistake is attempting to normalize SBP and HR to values 
seen in those with baseline normal cardiac structure and function. However, for patients 
with severely reduced EF, a ‘normal’ SBP may be unattainable, and tachycardia may be the 
key contributor to cardiac output. 
 For patients with low SBP, administering a fluid bolus is nearly a reflexive action.  
But in the setting of hypoperfusion secondary to heart failure rather than hypovolemia, this 
may result in worsening pulmonary edema. On the other hand, infection and overdiuresis 
are common precipitants that may respond quite well to fluid.  At the bedside, assessing 
volume status is challenging, especially in patients with advanced HF.  As noted above, 
ultrasound may be useful, but response to initial treatment will often be the best guide to 
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subsequent management.  Although rarely applied in the ED setting due to concerns of 
precipitating circulatory failure, AHF patients with low SBP who are congested may require 
decongestive therapies.  Optimizing volume status through diuresis and vasodilation may 
lead to significant clinical improvement. In some refractory cases, inotropes and 
vasopressors are required to augment cardiac output and blood pressure. 
 
Inotropes and Vasopressors 
Table 3 shows commonly used inotropes and vasopressors.  Although inotropes and 
vasodilators improve hemodynamics, to date, none are associated with better clinical 
outcomes.  In fact, available inotropes have been associated with harm, though the 
evidence base is small and inconsistent. 69-72  In terms of vasopressors, there is a paucity of 
robust data to strongly recommend one vasopressor over another. Subgroup analysis from 
a large randomized trial found increased mortality in patients with cardiogenic shock who 
were randomized to dopamine compared with those randomized to norepinephrine.73 
Table 3 Initial Dose Infusion range Recommendation Class 
(Evidence level) 
Dobutamine 2-3 ucg/kg/min 2-20 ucg/kg/min IIB (Level B 
Milrinone  0.375-0.75 
ucg/kg/min* 
IIB  (Level B) 
Levosimendan  0.05 -0.2 ug/kg/min* Not available in US 
Dopamine 2-5 ucg/kg/min 2-50 ucg/kg/min IIB  (Level B) 
Norepinephrine  0.2 – 1.0 ucg/kg/min  
Nitroglycerin 5-20 ucg/min 
(rapidly titrate to 
effect) 
5-200 ucg/min 
(rapidly titrate to 
effect) 
IIB  (Level A) 
Nitroprusside 5-10 mcg/min 0.25 ucg/kg/min – 
10 ucg/kg/min 
IIB  (Level A) 
Nesiritide  0.01 ucg/kg/min* IIB  (Level A) 
ACE-I (enalaprilat) 1.25-5mg IV 
bolus q6 hrs 
NA NA 
*Consider bolus dosing 
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The Hypertensive Patient  
Approximately half of patients admitted with AHF present with hypertension (SBP ≥ 140 
mmHg).60,68  In general, these patients tend to be older, have preserved EF,60 and present with 
a more acute onset of symptoms, often less than 24 hours. Pulmonary edema in such patients 
is more likely to be caused by vascular redistribution than by hypervolemia. As such, 
vasodilators are the mainstay of treatment. 
Of the guideline-recommended vasodilator options [nitroglycerin (NTG), nitroprusside, 
or nesiritide], we recommend NTG as first line.74 Clinicians and nurses are familiar with NTG; it 
can be administered rapidly via sublingual and intravenous routes, and it’s inexpensive. Bolus 
doses of up to 2-3 mg are well tolerated and effective, though many clinicians are reluctant to 
give such large doses.75,76 Anecdotally, NTG as an IV drip is often withheld due to the 
requirement for an intensive care unit (ICU)bed.  However, the rapid onset/offset of NTG make 
it an ideal titratable drug to initiate before transitioning to topical NTG or alternative therapies.  
Nitroprusside and nesiritide are alternatives to NTG. As with NTG, neither nitroprusside 
nor nesiritide has been shown to decrease mortality or morbidity in AHF.77 However, both are 
effective vasodilators, with nitroprusside being the more potent. While NTG predominantly acts 
on the venous circulation until at higher doses, nitroprusside acts rapidly on both the arterial 
and venous circulation.  It may precipitously lower BP; thus careful monitoring is required. 
Nesiritide is one of the most well studied vasodilators in terms of large randomized controlled 
trials.  After initial concerns regarding safety, a large randomized, controlled trial (ASCEND-HF; 
n= 7,141) found no relative benefit or harm associated with nesiritide in terms of mortality, 
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hospital readmission, or dyspnea.78 It may be a reasonable option if a vasodilator is desired but 
ICU beds are unavailable. 
Despite the lack of compelling evidence supporting acute angiotensin converting 
enzyme inhibitor (ACEI) use in the ED, these agents are sufficiently used in the setting of AHF to 
be mentioned in the American College of Emergency Physicians 79.  A common misperception: 
the benefit of ACEI in chronic HF with reduced EF extends to the acute setting. Lack of evidence 
does not equal a bad therapy; only that sufficiently powered, well-designed trials have not yet 
been performed.   
Morphine’s historic use in AHF continues today.  Retrospective observational data 
suggests an increased risk of death in patients treated with morphine for AHF.80 As it offers no 
defined benefit, we recommend against routine morphine use in AHF.  
 
The Normotensive Patient (SBP 100-140mmHg) 
AHF patients presenting with SBP ranging from 100-140mmHg rarely arrive to the ED in 
extremis.60 The prototypical patient reports an indolent course over days or even weeks, and 
may report significant weight gain. Decongestion with intravenous (IV) loop diuretics is the 
primary therapy. Bolus or continuous infusion diuretic administration makes no difference.81 A 
randomized trial comparing IV doses of the patient’s standard oral dose to larger IV doses (2.5 
times the standard oral dose) found that larger doses resulted in more diuresis and marginally 
better dyspnea over the first 72 hours, but also increased the likelihood of creatinine 
elevation.81 In addition to diuretic therapy, low-dose vasodilators should be considered in 
normotensive patients. 
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A Hospitalist’s Perspective in Brief: 
From the hospitalist perspective, whether so many AHF patients warrant admission is 
debatable.82 Nevertheless, at the present time, most AHF patients are hospitalized. Thus, it is 
worth highlighting the different clinical framework between hospitalists and ED physicians for 
the management of AHF. While risking overgeneralization, ED physicians work with limited data 
in a fast-paced environment where rapid disposition and ensured access to short-term follow-
up are paramount.   Thorough diagnostic evaluation of cardiac structure, function, and AHF 
etiology are secondary objectives for ED physicians.  Hospitalists tend to expect greater 
diagnostic clarity and institute management plans that address comorbid conditions and the 
long-term consequences of cardiac remodeling.  
  
In regards to clinical management, the use of diuretics is often a major point of 
contention between hospitalists and ED physicians. IV loop diuretics are the cornerstone of 
acute therapy for AHF patients. Nearly 90% of patients hospitalized with AHF receive IV loop 
diuretics in the ￼83.￼68ACC/AHA (American College of Cardiology/American Heart Association) 
and ESC guidelines, though large randomized controlled trials have yet to be performed (and it 
is doubtful they ever will be).  Given the absence of other therapies to readily decongest 
patients, why IV diuretics are withheld or underdosed appears perplexing.  Although 
retrospective studies suggest harm associated with early aggressive IV loop diuretic use, no 
prospective evidence supports this hypothesis.￼84,85. Withholding IV diuretics in the ED may be 
perceived by the inpatient teams as delaying patient care. 
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If diuretics are given in the ED, they are often underdosed. By their very mechanism of action,86 
loop diuretics must be secreted via active transport in the proximal tubules of the kidney. 
Rather than minimize doses, especially in patients with impaired renal function, higher doses 
are required to reach the dose-response threshold.86  
 
Disposition and Outcomes 
Contrary to commonly held belief, most patients who visit the ED are sent home; only 
9.3% of the annual 130 million ED visits in the US result in hospitalization. However, nearly all 
ED patients with AHF are hospitalized.  From 2006 to 2011, the annual US hospitalization rate 
for AHF patients in the ED has consistently been around 85%.87 Given financial penalties tied to 
excess re-hospitalization, this admission rate warrants scrutiny.  
 Administrative data analyses suggest up to 50% of patients with AHF could be 
discharged or observed briefly and released.88  AHF is a progressive illness and the short-term 
prognosis following hospitalization is unacceptably poor.  This makes the concept of a low-risk 
AHF patient difficult for the emergency physician to embrace. Yet within the spectrum of risk, 
some are lower than others.   Identifying patients safe to be sent home from the ED remains 
challenging, as the majority of risk-stratification work in AHF focuses on defining and 
characterizing high risk in-patients, making extrapolation to the ED setting challenging.89  While 
some risk instruments, such as the AHF Index, EMHRG, STRATIFY, or the Ottawa Heart Failure 
Index are promising,90-92 none have gained widespread acceptance, either due to the need for 
further validation, differences in patient populations, or limited information on outcomes for 
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discharged patients identified as lower risk.93 Identifying patients low enough risk for safe 
discharge from the ED remains a key focus for research. 
 The absence of high risk features  (i.e. low BP, high BNP levels, worsening renal function, 
elevated troponin, and hyponatremia) does not equal no risk,89,94,95  but it does equate to lower 
risk.  In the future, absence of myocardial injury by high sensitivity troponin assays may help 
identify low risk patients.96 As risk-stratification improves, appropriate selection of patients for 
treatment in observation or short-stay units in AHF may become easier.97,98 These units may 
provide more time to risk stratify patients, gauge response to therapy, provide education, 
engage case management and social work as needed, reconcile medications, and facilitate close 
follow up. These tasks are often challenging to complete during a brief ED stay.  Furthermore, 
given the reluctance to discharge lower-risk AHF patients from the ED, the use of observation 
medicine as a ‘bridge’ may be more clinically feasible and acceptable to ED physicians.3,94 
For higher risk patients, hospitalization may offer benefit to improve symptoms, 
optimize volume status, and ensure initiation of guideline directed chronic medical therapy. 
AHF pharmacologic therapies, on their own, have not been proven to affect post-discharge 
outcomes.2  However, hospitalization may help higher risk patients achieve symptomatic relief, 
euvolemia/complete decongestion, and medical optimization. Patients with new onset or de 
novo HF should also be admitted, as potentially reversible or modifiable causes may be 
identified.  These patients will also need education about self-managing their new chronic 
illness. Overall however, indiscriminate admission is unlikely to translate into patient-centered 
benefit or justifiable cost. As mentioned previously, identifying who can be safely observed or 
discharged from the ED remains an unmet need. 
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Conclusion: 
The ED management of AHF centers around diagnosis, stabilization, identification of the 
precipitant of AHF, initial treatment, and risk-stratification.  We recommend initial ED 
treatment be guided by presenting phenotype but treatment largely centers around diuretics 
and vasodilators.  Although currently available therapies improve symptoms, none definitively 
improve outcomes.  Identification of life saving therapies for the early treatment of AHF 
remains an unmet need, though whether a short-term treatment can influence longer term 
post-discharge outcomes remains unclear. As US EDs continue to admit nearly all AHF patients, 
identifying appropriate low-risk patients for discharge and close follow-up would result in 
tremendous value to the health care system.  
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